ArticleNeuro-oncology2023

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.

Romain Sigaud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.